Cargando…

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer

SIMPLE SUMMARY: Biomarkers found in the blood of patients with hormone receptor positive and HER2 negative metastatic breast cancer are being investigated to understand how patients respond to treatments. Circulating biomarkers have the potential advantage of giving important information with a simp...

Descripción completa

Detalles Bibliográficos
Autores principales: Migliaccio, Ilenia, Leo, Angela, Galardi, Francesca, Guarducci, Cristina, Fusco, Giulio Maria, Benelli, Matteo, Di Leo, Angelo, Biganzoli, Laura, Malorni, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199335/
https://www.ncbi.nlm.nih.gov/pubmed/34072070
http://dx.doi.org/10.3390/cancers13112640
_version_ 1783707352536449024
author Migliaccio, Ilenia
Leo, Angela
Galardi, Francesca
Guarducci, Cristina
Fusco, Giulio Maria
Benelli, Matteo
Di Leo, Angelo
Biganzoli, Laura
Malorni, Luca
author_facet Migliaccio, Ilenia
Leo, Angela
Galardi, Francesca
Guarducci, Cristina
Fusco, Giulio Maria
Benelli, Matteo
Di Leo, Angelo
Biganzoli, Laura
Malorni, Luca
author_sort Migliaccio, Ilenia
collection PubMed
description SIMPLE SUMMARY: Biomarkers found in the blood of patients with hormone receptor positive and HER2 negative metastatic breast cancer are being investigated to understand how patients respond to treatments. Circulating biomarkers have the potential advantage of giving important information with a simple withdrawal of peripheral blood. Here, we review and discuss the recent achievements in the development of circulating biomarkers in patients with metastatic breast cancer treated with CDK4/6 inhibitors and endocrine therapy. ABSTRACT: CDK4/6 inhibitors (CDK4/6i) and endocrine therapy are the standard treatment for patients with hormone receptor-positive and HER2 negative (HR+/HER2−) metastatic breast cancer. Patients might show intrinsic and acquired resistance, which leads to treatment failure and progression. Circulating biomarkers have the potential advantages of recognizing patients who might not respond to treatment, monitoring treatment effects and identifying markers of acquired resistance during tumor progression with a simple withdrawal of peripheral blood. Genomic alterations on circulating tumor DNA and serum thymidine kinase activity, but also circulating tumor cells, epigenetic or exosome markers are currently being tested as markers of CDK4/6i treatment response, even though none of these have been integrated into clinical practice. In this review, we discuss the recent advancements in the development of circulating biomarkers of CDK4/6i response in patients with HR+/HER2−breast cancer.
format Online
Article
Text
id pubmed-8199335
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81993352021-06-14 Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer Migliaccio, Ilenia Leo, Angela Galardi, Francesca Guarducci, Cristina Fusco, Giulio Maria Benelli, Matteo Di Leo, Angelo Biganzoli, Laura Malorni, Luca Cancers (Basel) Review SIMPLE SUMMARY: Biomarkers found in the blood of patients with hormone receptor positive and HER2 negative metastatic breast cancer are being investigated to understand how patients respond to treatments. Circulating biomarkers have the potential advantage of giving important information with a simple withdrawal of peripheral blood. Here, we review and discuss the recent achievements in the development of circulating biomarkers in patients with metastatic breast cancer treated with CDK4/6 inhibitors and endocrine therapy. ABSTRACT: CDK4/6 inhibitors (CDK4/6i) and endocrine therapy are the standard treatment for patients with hormone receptor-positive and HER2 negative (HR+/HER2−) metastatic breast cancer. Patients might show intrinsic and acquired resistance, which leads to treatment failure and progression. Circulating biomarkers have the potential advantages of recognizing patients who might not respond to treatment, monitoring treatment effects and identifying markers of acquired resistance during tumor progression with a simple withdrawal of peripheral blood. Genomic alterations on circulating tumor DNA and serum thymidine kinase activity, but also circulating tumor cells, epigenetic or exosome markers are currently being tested as markers of CDK4/6i treatment response, even though none of these have been integrated into clinical practice. In this review, we discuss the recent advancements in the development of circulating biomarkers of CDK4/6i response in patients with HR+/HER2−breast cancer. MDPI 2021-05-27 /pmc/articles/PMC8199335/ /pubmed/34072070 http://dx.doi.org/10.3390/cancers13112640 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Migliaccio, Ilenia
Leo, Angela
Galardi, Francesca
Guarducci, Cristina
Fusco, Giulio Maria
Benelli, Matteo
Di Leo, Angelo
Biganzoli, Laura
Malorni, Luca
Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
title Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
title_full Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
title_fullStr Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
title_full_unstemmed Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
title_short Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
title_sort circulating biomarkers of cdk4/6 inhibitors response in hormone receptor positive and her2 negative breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199335/
https://www.ncbi.nlm.nih.gov/pubmed/34072070
http://dx.doi.org/10.3390/cancers13112640
work_keys_str_mv AT migliaccioilenia circulatingbiomarkersofcdk46inhibitorsresponseinhormonereceptorpositiveandher2negativebreastcancer
AT leoangela circulatingbiomarkersofcdk46inhibitorsresponseinhormonereceptorpositiveandher2negativebreastcancer
AT galardifrancesca circulatingbiomarkersofcdk46inhibitorsresponseinhormonereceptorpositiveandher2negativebreastcancer
AT guarduccicristina circulatingbiomarkersofcdk46inhibitorsresponseinhormonereceptorpositiveandher2negativebreastcancer
AT fuscogiuliomaria circulatingbiomarkersofcdk46inhibitorsresponseinhormonereceptorpositiveandher2negativebreastcancer
AT benellimatteo circulatingbiomarkersofcdk46inhibitorsresponseinhormonereceptorpositiveandher2negativebreastcancer
AT dileoangelo circulatingbiomarkersofcdk46inhibitorsresponseinhormonereceptorpositiveandher2negativebreastcancer
AT biganzolilaura circulatingbiomarkersofcdk46inhibitorsresponseinhormonereceptorpositiveandher2negativebreastcancer
AT malorniluca circulatingbiomarkersofcdk46inhibitorsresponseinhormonereceptorpositiveandher2negativebreastcancer